N,7-Dimethylchinolinium | 18241-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N,7-Dimethylchinolinium
• 英文别名: 1,7-dimethyl-quinolinium；1,7-Dimethylquinolin-1-ium
• CAS: 18241-39-9
• 化学式: C₁₁H₁₂N
• 分子量: 158.223
• InChiKey: QLHQEPBWTJOUDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  3.9
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR<br/>[FR] COMPOSÉS DE CARBOXYAMIDE ET LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR CCR2DE LA CHIMIOKINE
  申请人：EPIX DELAWARE INC

  公开号：WO2009076404A1

  公开（公告）日：2009-06-18

  Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described; wherein (B/A) is an optionally substituted fused aromatic or partially aromatic bicyclic ring containing at least one nitrogen atom.

  描述了特定的化学物质，即作为趋化因子CCR2受体拮抗剂的Formula (I)化合物，包括其药用组合物和用途，用于治疗或预防与单核细胞、淋巴细胞或白细胞聚积相关的疾病；其中(B/A)是一个可选择地取代的融合芳香或部分芳香的双环环，其中至少含有一个氮原子。
• Carboxamide Compounds and Their Use
  申请人：Ben-Zeev Efrat

  公开号：US20100324035A1

  公开（公告）日：2010-12-23

  Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

  化学因子受体拮抗剂，特别是化合物式(I-A)的拮抗剂，作为化学因子CCR2受体的拮抗剂，包括其药物组合物和用途，用于治疗或预防与单核细胞聚集、淋巴细胞聚集或白细胞聚集相关的疾病。
• [EN] DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS<br/>[FR] DIHYDRONAPHTYRIDINYLE ET COMPOSÉS APPARENTÉS UTILISABLES DANS LE CADRE DU TRAITEMENT DE TROUBLES OPHTALMOLOGIQUES
  申请人：CYTOPATHFINDER INC

  公开号：WO2010129843A1

  公开（公告）日：2010-11-11

  The invention provides methods of using dihydronaphthyridinyl and related compounds to treat ophthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided.

  这项发明提供了使用二氢萘啉基和相关化合物治疗眼科疾病的方法，如湿性年龄相关性黄斑变性、糖尿病视网膜病变和高度近视。还提供了制备二氢萘啉基和相关化合物的药物组合物和合成方法。
• Novel benzothiazepine and bensothiepine compounds
  申请人：Sasahara Takehiko

  公开号：US20070190041A1

  公开（公告）日：2007-08-16

  A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substitutent:

  提供了一种药物，可用作治疗和预防高脂血症的治疗剂和预防剂，以及一种药物，可用作治疗和预防与胆汁淤积有关的肝脏疾病，特别是原发性胆汁性肝硬化和原发性硬化性胆管炎的治疗剂和预防剂，以及一种药物，可用作治疗和预防肥胖症、脂肪肝和脂肪性肝炎的治疗剂和预防剂。化合物的苯并噻吩或苯并噻环代表如下式（1A），具有硫酰胺键和季铵取代基：
• Novel quaternary ammonium compounds
  申请人：Sasahara Takehiko

  公开号：US20070203115A1

  公开（公告）日：2007-08-30

  A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):

  一种抑制回肠胆汁酸转运蛋白活性的方法，包括向该受试者施用一种由式（1）所代表的化合物的有效量：